In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis

Session Poster Session 5

Speaker Gregory Yh Lip

Event : ESC Congress 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Oral Anticoagulation
  • Session type : Poster Session

Authors : GYH Lip (Liverpool,GB), H-C Diener (Duisberg,DE), SJ Dubner (Caba,AR), JL Halperin (New York,US), KJ Rothman (Durham,US), C-S Ma (Beijing,CN), S Lu (Ridgefield,US), M Paquette (Burlington,CA), L Riou Franca (Ingelheim am Rhein,DE), K Zint (Ingelheim am Rhein,DE), C Teutsch (Ingelheim am Rhein,DE), MV Huisman (Leiden,NL)

G.Y.H. Lip1 , H.-C. Diener2 , S.J. Dubner3 , J.L. Halperin4 , K.J. Rothman5 , C.-S. Ma6 , S. Lu7 , M. Paquette8 , L. Riou Franca9 , K. Zint9 , C. Teutsch9 , M.V. Huisman10 , 1University of Liverpool, Institute of Cardiovascular Science - Liverpool - United Kingdom , 2University of Duisburg-Essen - Duisberg - Germany , 3Clínica y Maternidad Suizo Argentina - Caba - Argentina , 4Icahn School of Medicine at Mount Sinai - New York - United States of America , 5RTI Health Solutions, Research Triangle Institute - Durham - United States of America , 6Beijing Anzhen Hospital - Beijing - China , 7Boehringer Ingelheim Pharmaceuticals, Inc - Ridgefield - United States of America , 8Boehringer Ingelheim - Burlington - Canada , 9Boehringer Ingelheim International - Ingelheim am Rhein - Germany , 10Leiden University Medical Center - Leiden - Netherlands (The) ,

On behalf: The GLORIA-AF Registry investigators and patients

Oral Anticoagulation

European Heart Journal ( 2019 ) 40 ( Supplement ), 2987

Background: Oral anticoagulation (OAC) persistence is important for optimizing stroke prevention in patients with atrial fibrillation (AF); non-vitamin K oral anticoagulants (NOACs) generally show better persistence than vitamin K antagonists (VKAs), while the impact of dosing regimens remains unclear. We compared treatment persistence of NOACs and VKAs, and of NOAC dosing regimens in the prospective GLORIA-AF registry program.

Methods: Patients newly diagnosed with AF were enrolled in Phase III of GLORIA-AF (2014–2016) from 4 geographical regions (North America [NA], Europe, Asia and Latin America). Treatment persistence after 1 year for i) NOAC (dabigatran, rivaroxaban, apixaban, edoxaban) vs VKA, and ii) twice daily (bid, dabigatran, apixaban) vs once daily (od; rivaroxaban, edoxaban) NOAC treatment was analysed using multivariable Cox analysis; propensity score trimming was used to reduce bias due to unmeasured confounders. Missing data was handled by multiple imputation.

Results: Overall, 21,592 patients were enrolled (4970 [23%] patients on VKAs, 12,797 [59%] on NOACs, 2391 [11%] on antiplatelets, and 1426 [6.6%] received no therapy; 8 [0.04%] received other treatment). After trimming, 11,935 and 4484 patients treated with NOACs and VKAs, respectively, were compared. NOACs had better treatment persistence than VKAs (discontinuation hazard ratio [HR]=0.75, 95% confidence interval [CI] 0.69–0.81). Other relevant associations were decreased OAC persistence for symptomatic AF, NA and Asia regions (Table). There was no difference in treatment persistence for patients on a bid (N=7842) vs od (N=4098) NOAC (discontinuation HR=0.94, 95% CI 0.86–1.02).

Conclusion: In this 1-year interim analysis of GLORIA-AF Phase III, treatment persistence was improved with NOACs vs VKAs, whereas for NOACs, dosing regimen (bid vs od) had no impact on treatment persistence.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are